HRT Hormone Replacement Therapy
HRT Hormone Replacement Therapy

What is tibolone (Livial)?

Home
What's New - Blog
Abortion
Amenorrhoea - Absent Periods
Birth Control
Bladder Symptoms
Cancer in Women
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometriosis
Female Sexual Problems
Fibroids
HRT Risks & Benefits
Hysterectomy
Infections
Infertility
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Miscarriage
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Vaginal Discharge
Vaginal Prolapse
Viagra, Libido and Sex Drive.
The Author
Consultations
Contact Us

Authors:

Rymer J. Fogelman I. Chapman MG.

Institution:

Department of Obstetrics/Gynaecology, New Guy's House, Guy's Hospital, London SE1 9RT; United Kingdom.

Title:

The incidence of vaginal bleeding with tibolone treatment (1994-543).

Source:

British Journal of Obstetrics and Gynaecology. Vol 101(1) (pp3-56), 1994.

Abstract:

Objective To determine the incidence of breakthrough bleeding and its significance in recently postmenopausal women who take tibolone (Livial- Organon). Design A two year comparative nonrandomised prospective study of women taking tibolone (2.5 mg) and control subjects not on medication. Setting Teaching hospital menopause and well women clinic. Subjects One hundred women who were recently menopausal (between 6 and 36 months since last menstrual period). Fifty were commenced on tibolone and 50 received no medication. Main outcome measures Episodes of bleeding throughout the two year study period were recorded. Oestradiol levels were measured at baseline and at six, 12 and 24 months. The age of menopause and time since last menstrual period (LMP) were noted. Results Twenty percent (12/59) (95% CI 11.0% to 32.8%) of women in the tibolone group had breakthrough bleeding compared with 9.4% (5/23) (95% CI 3.1% to 20.7%) in the control group. Of the women who bled in the tibolone group, 50% had LMP between six and 12 months prior to entering the study, and 83% were younger than the average age of menopause. Sixty-seven percent had detectable oestradiol levels on at least one occasion over the two years (five women had detectable oestradiol levels and did not bleed). None had evidence of endometrial stimulation at dilatation and curettage. Eighty percent of women who bled in the control group were between six and 12 months since LMP on entry into the study, and 80% had detectable oestradiol levels during the study. At dilatation and curettage there was no evidence of endometrial stimulation. Conclusions A minority of women will bleed on tibolone therapy. Women who are likely to bleed are younger, are recently menopausal, and may have remaining endogenous oestrogen production.


Back Home Up Next

Please click on the required question.

Do you have an unanswered women's health question?

Please let us have your general question on our NEW FORUM / MESSAGE BOARDS facility and we will try to answer it for you. I am sure that you will appreciate that we cannot offer advice on the management of an individual's specific problem.


Thank you for your visiting us at 2WomensHealth.com.

This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.

I do hope that you find the answers to your questions in the patient information and medical advice provided. If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.

DISCLAIMER

The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.